AGÕæÈ˹ٷ½

STOCK TITAN

[Form 4] Biogen Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Biogen Inc. (BIIB) â€� Form 4 insider transaction

Independent director Dr. Lloyd Minor reported the acquisition of 2,370 shares of Biogen common stock on 17-Jun-2025. The transaction code “A� indicates that the shares were awarded rather than purchased on the open market; the reported price is $0, consistent with a restricted stock or director equity grant. Following the grant, Dr. Minor’s total direct ownership stands at 2,370 shares. No derivative securities were involved, and there were no dispositions.

The filing is routine director compensation disclosure and does not reveal any change in strategy, operations, or financial condition. However, fresh equity ownership marginally strengthens alignment between the director and shareholder interests.

Biogen Inc. (BIIB) � Transazione interna Form 4

Il direttore indipendente Dr. Lloyd Minor ha segnalato l'acquisizione di 2.370 azioni ordinarie di Biogen il 17 giugno 2025. Il codice di transazione “A� indica che le azioni sono state assegnate e non acquistate sul mercato aperto; il prezzo riportato è di 0$, coerente con un premio azionario vincolato o una concessione di azioni per il direttore. Dopo l’assegnazione, la proprietà diretta totale del Dr. Minor ammonta a 2.370 azioni. Non sono stati coinvolti titoli derivati e non ci sono state cessioni.

La comunicazione rappresenta una normale divulgazione della compensazione del direttore e non indica alcun cambiamento nella strategia, nelle operazioni o nella situazione finanziaria. Tuttavia, la nuova proprietà azionaria rafforza leggermente l’allineamento tra gli interessi del direttore e quelli degli azionisti.

Biogen Inc. (BIIB) � Transacción interna Formulario 4

El director independiente Dr. Lloyd Minor reportó la adquisición de 2,370 acciones ordinarias de Biogen el 17 de junio de 2025. El código de transacción “A� indica que las acciones fueron otorgadas y no compradas en el mercado abierto; el precio reportado es de $0, consistente con una concesión de acciones restringidas o de capital para directores. Tras la concesión, la propiedad directa total del Dr. Minor es de 2,370 acciones. No se involucraron valores derivados ni hubo disposiciones.

La presentación es una divulgación rutinaria de la compensación del director y no revela cambios en la estrategia, operaciones o situación financiera. Sin embargo, la nueva propiedad accionaria fortalece ligeramente la alineación entre los intereses del director y los accionistas.

Biogen Inc. (BIIB) � Form 4 내부� 거래 보고

ë…립 ì´ì‚¬ Dr. Lloyd Minorê°€ 2025ë…� 6ì›� 17ì¼ì— Biogen 보통ì£� 2,370ì£� ì·¨ë“ì� 보고했습니다. 거래 코드 “Aâ€ëŠ” 주ì‹ì� 공개 시장ì—서 구매ë� ê²ƒì´ ì•„ë‹ˆë� ë¶€ì—¬ëœ ê²ƒìž„ì� 나타내며, ë³´ê³ ë� ê°€ê²©ì€ 0달러ë¡� 제한 ì£¼ì‹ ë˜ëŠ” ì´ì‚¬ ì£¼ì‹ ë³´ì¡°ê¸ˆê³¼ ì¼ì¹˜í•©ë‹ˆë‹�. ë¶€ì—� í›� Dr. Minorì� ì§ì ‘ 소유 ì£¼ì‹ ì´ìˆ˜ëŠ� 2,370ì£�입니ë‹�. íŒŒìƒ ì¦ê¶Œì€ í¬í•¨ë˜ì§€ 않았으며 처분ë� 없었습니ë‹�.

ì� ë³´ê³ ëŠ� ì´ì‚¬ ë³´ìƒ ê³µê°œì� ì¼í™˜ìœ¼ë¡œ ì „ëžµ, ìš´ì˜ ë˜ëŠ” 재무 ìƒíƒœì� 변화를 나타내지 않습니다. 그러ë‚� 새로ìš� ì£¼ì‹ ì†Œìœ ê¶Œì€ ì´ì‚¬ì™€ 주주 ê°� ì´í•´ê´€ê³„ì˜ ì¼ì¹˜ë¥� 다소 강화합니ë‹�.

Biogen Inc. (BIIB) � Transaction d’initié Formulaire 4

Le directeur indépendant Dr. Lloyd Minor a déclaré l�acquisition de 2 370 actions ordinaires de Biogen le 17 juin 2025. Le code de transaction « A » indique que les actions ont été attribuées et non achetées sur le marché libre ; le prix déclaré est de 0 $, conforme à une attribution d’actions restreintes ou une attribution d’actions pour un administrateur. Après cette attribution, la détention directe totale du Dr Minor s’élève à 2 370 actions. Aucun titre dérivé n’a été impliqué, et aucune cession n’a eu lieu.

Le dépôt est une divulgation routinière de la rémunération des administrateurs et ne révèle aucun changement de stratégie, d’opérations ou de situation financière. Cependant, cette nouvelle détention d’actions renforce légèrement l’alignement des intérêts entre l’administrateur et les actionnaires.

Biogen Inc. (BIIB) � Insider-Transaktion Form 4

Der unabhängige Direktor Dr. Lloyd Minor meldete am 17. Juni 2025 den Erwerb von 2.370 Stammaktien von Biogen. Der Transaktionscode „A� weist darauf hin, dass die Aktien verliehen und nicht auf dem offenen Markt gekauft wurden; der gemeldete Preis beträgt 0 $, was mit einer beschränkten Aktienzuteilung oder einer Aktienzuteilung für Direktoren übereinstimmt. Nach der Zuteilung hält Dr. Minor insgesamt 2.370 Aktien. Es waren keine Derivate beteiligt, und es gab keine Veräußerungen.

Die Meldung ist eine routinemäßige Offenlegung der Vergütung des Direktors und zeigt keine Änderungen in Strategie, Betrieb oder finanzieller Lage. Die neue Aktienbeteiligung stärkt jedoch geringfügig die Übereinstimmung der Interessen von Direktor und Aktionären.

Positive
  • Director Lloyd Minor acquired 2,370 BIIB shares, modestly increasing insider ownership and aligning board and shareholder interests.
Negative
  • None.

Insights

TL;DR: Director received 2,370-share equity grant; routine, modestly positive alignment signal.

Form 4 shows Dr. Minor’s first disclosed stake (2,370 shares) via a zero-cost equity award, typical for director compensation. The lack of market purchase tempers the signaling value versus an open-market buy, but it still increases insider skin-in-the-game. Size is immaterial relative to Biogen’s 146 million shares outstanding; therefore, limited market impact is expected.

TL;DR: Standard director grant—enhances governance alignment, no corporate risk flagged.

The award is consistent with Biogen’s equity-based director pay policy and signals adherence to governance best practices. No red flags such as accelerated vesting, option backdating, or unusual trade timing are present. Thus, the disclosure is neutral from a risk perspective and slightly positive for aligning board incentives.

Biogen Inc. (BIIB) � Transazione interna Form 4

Il direttore indipendente Dr. Lloyd Minor ha segnalato l'acquisizione di 2.370 azioni ordinarie di Biogen il 17 giugno 2025. Il codice di transazione “A� indica che le azioni sono state assegnate e non acquistate sul mercato aperto; il prezzo riportato è di 0$, coerente con un premio azionario vincolato o una concessione di azioni per il direttore. Dopo l’assegnazione, la proprietà diretta totale del Dr. Minor ammonta a 2.370 azioni. Non sono stati coinvolti titoli derivati e non ci sono state cessioni.

La comunicazione rappresenta una normale divulgazione della compensazione del direttore e non indica alcun cambiamento nella strategia, nelle operazioni o nella situazione finanziaria. Tuttavia, la nuova proprietà azionaria rafforza leggermente l’allineamento tra gli interessi del direttore e quelli degli azionisti.

Biogen Inc. (BIIB) � Transacción interna Formulario 4

El director independiente Dr. Lloyd Minor reportó la adquisición de 2,370 acciones ordinarias de Biogen el 17 de junio de 2025. El código de transacción “A� indica que las acciones fueron otorgadas y no compradas en el mercado abierto; el precio reportado es de $0, consistente con una concesión de acciones restringidas o de capital para directores. Tras la concesión, la propiedad directa total del Dr. Minor es de 2,370 acciones. No se involucraron valores derivados ni hubo disposiciones.

La presentación es una divulgación rutinaria de la compensación del director y no revela cambios en la estrategia, operaciones o situación financiera. Sin embargo, la nueva propiedad accionaria fortalece ligeramente la alineación entre los intereses del director y los accionistas.

Biogen Inc. (BIIB) � Form 4 내부� 거래 보고

ë…립 ì´ì‚¬ Dr. Lloyd Minorê°€ 2025ë…� 6ì›� 17ì¼ì— Biogen 보통ì£� 2,370ì£� ì·¨ë“ì� 보고했습니다. 거래 코드 “Aâ€ëŠ” 주ì‹ì� 공개 시장ì—서 구매ë� ê²ƒì´ ì•„ë‹ˆë� ë¶€ì—¬ëœ ê²ƒìž„ì� 나타내며, ë³´ê³ ë� ê°€ê²©ì€ 0달러ë¡� 제한 ì£¼ì‹ ë˜ëŠ” ì´ì‚¬ ì£¼ì‹ ë³´ì¡°ê¸ˆê³¼ ì¼ì¹˜í•©ë‹ˆë‹�. ë¶€ì—� í›� Dr. Minorì� ì§ì ‘ 소유 ì£¼ì‹ ì´ìˆ˜ëŠ� 2,370ì£�입니ë‹�. íŒŒìƒ ì¦ê¶Œì€ í¬í•¨ë˜ì§€ 않았으며 처분ë� 없었습니ë‹�.

ì� ë³´ê³ ëŠ� ì´ì‚¬ ë³´ìƒ ê³µê°œì� ì¼í™˜ìœ¼ë¡œ ì „ëžµ, ìš´ì˜ ë˜ëŠ” 재무 ìƒíƒœì� 변화를 나타내지 않습니다. 그러ë‚� 새로ìš� ì£¼ì‹ ì†Œìœ ê¶Œì€ ì´ì‚¬ì™€ 주주 ê°� ì´í•´ê´€ê³„ì˜ ì¼ì¹˜ë¥� 다소 강화합니ë‹�.

Biogen Inc. (BIIB) � Transaction d’initié Formulaire 4

Le directeur indépendant Dr. Lloyd Minor a déclaré l�acquisition de 2 370 actions ordinaires de Biogen le 17 juin 2025. Le code de transaction « A » indique que les actions ont été attribuées et non achetées sur le marché libre ; le prix déclaré est de 0 $, conforme à une attribution d’actions restreintes ou une attribution d’actions pour un administrateur. Après cette attribution, la détention directe totale du Dr Minor s’élève à 2 370 actions. Aucun titre dérivé n’a été impliqué, et aucune cession n’a eu lieu.

Le dépôt est une divulgation routinière de la rémunération des administrateurs et ne révèle aucun changement de stratégie, d’opérations ou de situation financière. Cependant, cette nouvelle détention d’actions renforce légèrement l’alignement des intérêts entre l’administrateur et les actionnaires.

Biogen Inc. (BIIB) � Insider-Transaktion Form 4

Der unabhängige Direktor Dr. Lloyd Minor meldete am 17. Juni 2025 den Erwerb von 2.370 Stammaktien von Biogen. Der Transaktionscode „A� weist darauf hin, dass die Aktien verliehen und nicht auf dem offenen Markt gekauft wurden; der gemeldete Preis beträgt 0 $, was mit einer beschränkten Aktienzuteilung oder einer Aktienzuteilung für Direktoren übereinstimmt. Nach der Zuteilung hält Dr. Minor insgesamt 2.370 Aktien. Es waren keine Derivate beteiligt, und es gab keine Veräußerungen.

Die Meldung ist eine routinemäßige Offenlegung der Vergütung des Direktors und zeigt keine Änderungen in Strategie, Betrieb oder finanzieller Lage. Die neue Aktienbeteiligung stärkt jedoch geringfügig die Übereinstimmung der Interessen von Direktor und Aktionären.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Minor Lloyd

(Last) (First) (Middle)
225 BINNEY STREET

(Street)
CAMBRIDGE MA 02142

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BIOGEN INC. [ BIIB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/17/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/17/2025 A 2,370 A $0 2,370 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
/s/ Samuel Ntonme, attorney-in-fact for Dr. Minor 06/18/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Biogen (BIIB) shares did Dr. Lloyd Minor acquire?

He acquired 2,370 common shares on 17-Jun-2025.

Was the transaction an open-market purchase?

No. Transaction code “A� and a $0 price indicate an equity award, not a market purchase.

What is Dr. Minor’s total Biogen share ownership after the grant?

His direct beneficial ownership totals 2,370 shares.

Does the Form 4 include any derivative securities activity?

No. Table II shows no derivative securities acquired or disposed of.

Is this filing likely to impact Biogen’s stock price?

Impact is expected to be minimal given the small size relative to Biogen’s share count.
Biogen Inc

NASDAQ:BIIB

BIIB Rankings

BIIB Latest News

BIIB Latest SEC Filings

BIIB Stock Data

18.65B
146.22M
0.21%
94.46%
2.54%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
United States
CAMBRIDGE